PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 127 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $96,000 | +6.7% | 12,000 | 0.0% | 0.01% | 0.0% |
Q1 2018 | $90,000 | +26.8% | 12,000 | 0.0% | 0.01% | +30.0% |
Q4 2017 | $71,000 | -19.3% | 12,000 | 0.0% | 0.01% | -23.1% |
Q3 2017 | $88,000 | +8.6% | 12,000 | 0.0% | 0.01% | 0.0% |
Q2 2017 | $81,000 | -28.3% | 12,000 | 0.0% | 0.01% | -31.6% |
Q1 2017 | $113,000 | +8.7% | 12,000 | 0.0% | 0.02% | -5.0% |
Q4 2016 | $104,000 | -18.1% | 12,000 | -40.0% | 0.02% | -13.0% |
Q3 2016 | $127,000 | – | 20,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |